Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1991 1
1992 1
1993 2
1996 2
1998 1
1999 2
2000 2
2001 2
2002 2
2005 1
2006 2
2007 1
2008 1
2009 3
2010 2
2011 4
2012 1
2013 2
2014 2
2015 3
2017 4
2018 2
2019 1
2020 2
2021 2
2022 3
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Diaz-Manera J, et al. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Lancet Neurol. 2021. PMID: 34800399 Clinical Trial.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Kishnani PS, et al. JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. JAMA Neurol. 2023. PMID: 37036722 Free PMC article. Clinical Trial.
Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis.
Sapaly D, Cheguillaume F, Weill L, Clerc Z, Biondi O, Bendris S, Buon C, Slika R, Piller E, Sundaram VK, da Silva Ramos A, Amador MDM, Lenglet T, Debs R, Le Forestier N, Pradat PF, Salachas F, Lacomblez L, Hesters A, Borderie D, Devos D, Desnuelle C, Rolland AS, Periou B, Vasseur S, Chapart M, Le Ber I, Fauret-Amsellem AL, Millecamps S, Maisonobe T, Leonard-Louis S, Behin A, Authier FJ, Evangelista T, Charbonnier F, Bruneteau G; PULSE study group. Sapaly D, et al. Brain. 2024 Aug 28:awae270. doi: 10.1093/brain/awae270. Online ahead of print. Brain. 2024. PMID: 39197036
Plant development: a TALE story.
Hamant O, Pautot V. Hamant O, et al. Among authors: pautot v. C R Biol. 2010 Apr;333(4):371-81. doi: 10.1016/j.crvi.2010.01.015. Epub 2010 Mar 19. C R Biol. 2010. PMID: 20371112 Free article. Review.
A cell wall-associated gene network shapes leaf boundary domains.
Bouré N, Peaucelle A, Goussot M, Adroher B, Soubigou-Taconnat L, Borrega N, Biot E, Tariq Z, Martin-Magniette ML, Pautot V, Laufs P, Arnaud N. Bouré N, et al. Among authors: pautot v. Development. 2022 Jun 1;149(11):dev200359. doi: 10.1242/dev.200359. Epub 2022 Jun 6. Development. 2022. PMID: 35575098 Free article.
SOD1 mutation can mask C9orf72 abnormal expansion.
Corcia P, Blasco H, Besson G, Camdessanché JP, Pautot V, Beltran S, Couratier P, Andres C, Camu W, Vourc'h P. Corcia P, et al. Among authors: pautot v. Eur J Neurol. 2017 Apr;24(4):e24. doi: 10.1111/ene.13257. Eur J Neurol. 2017. PMID: 28322003 No abstract available.
53 results